8-K current report · filed Jul 29, 2026

Teva Pharmaceutical Industries Ltd (TEVA) 8-K Current Report: July 29, 2026

Item 2.02Item EX-99.1TEVA overview

Short answer

Teva Pharmaceutical Industries Ltd (TEVA) filed an 8-K current report with the SEC on July 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Teva’s Q2 2026 financial results for the quarter ended June 30, 2026 announced July 29, 2026.

Teva Pharmaceutical Industries Ltd 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Teva’s Q2 2026 financial results for the quarter ended June 30, 2026 announced July 29, 2026
  • Detailed results, outlook and operating metrics contained in Exhibit 99.1 press release

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $4.142B, down 1% YoY, as 15% LC generics decline offset 43% LC growth in key innovative brands
  • AUSTEDO $696M, AJOVY $244M, and UZEDY $77M drove over $1B in combined quarterly revenue
  • 2026 outlook raised for all three innovative brands, combined revenue target approximately $3.7B, roughly 17% YoY growth
  • Emalex acquisition and ecopipam generated $726M of Q2 expenses, driving $0.49 GAAP loss per share and sharply lower operating profit
  • 2026 guidance maintained: revenue $16.5B-$16.85B, free cash flow $2.0B-$2.4B, non-GAAP EPS $1.91-$2.11 including $0.66 per-share Emalex impact

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Teva Pharmaceutical Industries Ltd 8-K filings

Get the next TEVA 8-K as it lands

Follow TEVA for push alerts, or ask the research agent what this filing means.